Akeso’s overseas drug promise fails to slow share decline
The Chinese drugmaker has been under pressure on equity markets since revealing plans for a share placement, overriding positive news for its key cancer therapy Key takeaways: Akeso’s shares have…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
FAST NEWS: Akeso raises $247 million through share placement
The Latest: Akeso Inc. (9926.HK) announced Sunday it has entered into placement agreements to issue 31.7 million shares to six investors priced at HK$61.28 per share, representing a 4.99% discount…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
RELATED ARTICLES
-
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Hengrui makes headway with novel drugs but investors bide their time
1276.HK600276.SHG
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Insilico revenue soars above $100 million on AI drug partnerships
